ArticleJournal of patient-reported outcomes2025
Sarcoma Assessment Measure-Paediatric Version (SAM-Paeds): development of a disease-specific patient reported outcome measure for children with sarcoma.
Article in Journal of patient-reported outcomes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSarcomas account for approximately 10-15% of all cancer in children aged ≤ 16. Poorer health-related quality of life (HRQoL) is recorded in comparison to other cancers; however, these studies are limited by generic HRQoL measures not being specific to patients with sarcoma. The aim of this study was to develop paediatric version of the Sarcoma Assessment Measure (SAM).
methodsThis mixed methods study comprised three stages: item generation, item reduction and establishing content validity. Children aged 8-16 years and parents of children aged 0-16 years with a diagnosis of sarcoma and within 5 years of completion of treatment were invited to participate.
resultsA total of 29 children and 38 parents from three sites participated in the study. Content analysis of the interview transcripts identified 277 post-diagnosis experience statements of which 128 'items' were included in an Item Reduction Questionnaire, grouped into six domains; physical, disability and inclusion; impact of diagnosis; emotional, impact on family, education. Items with a mean score < 5 and a content validity index of < 0.75 were removed. The final version of SAM-Paeds comprises 33 items (parent version) and 21 items (child version).
conclusionThis study has developed the first disease-specific HRQoL measure for paediatric sarcoma patients. SAM-Paeds is planned for inclusion within international sarcoma clinical trials and will be validated alongside current generic measures. Developed with the same methodology as the adult SAM questionnaire will facilitate the assessment of QoL longitudinally to assess the long-term impact of the diagnosis and treatment of sarcoma in childhood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.